NewYorkBIO Appoints New Class of Board of Directors
January 25, 2024, New York, NY – NewYorkBIO announced today its newly elected members of its Board of Directors, complete with leaders that bring a wealth of diverse experience and a shared commitment to fostering innovation across New York. As the Board of Directors for the leading advocate for New York’s life sciences community, these leaders play a pivotal role in guiding NewYorkBIO’s efforts to advance health innovation and solidify New York’s position as a worldwide leader in the life sciences.
This class of directors is comprised of a diverse array of professionals representing the breadth of companies contributing to the growth of biosciences in New York:
· Maya Bermingham, Regeneron
· Dan Brettler, Conner Strong & Buckelew
· Kara Cannon, Enzo Biochem
· Will Debarros, Marsh McLennan Agency
· Anthony Johnson, Kodikaz Therapeutic Solutions
· Dennis Purcell, Aisling Capital
· Peter Robinson, University of Rochester
· Paul Sekhri, vTv Therapeutics
· Priyanka Shah, Endless Frontier Labs
· Arthur Tinkelenberg, OurPlanet LLC
· Carlo Yuvienco, The Rockefeller University
Dan Brettler, Anthony Johnson, Dennis Purcell, Peter Robinson, and Arthur Tinkelenberg were reelected to serve an additional term and the newly elected board members will join a full NewYorkBIO Board of Directors with twenty-eight members.
“We are thrilled to welcome these leaders who will apply their diverse professional experiences and forward-looking approach to their role as NewYorkBIO fosters innovation and advances New York’s life science industry,” said Jennifer Hawks Bland, NewYorkBIO CEO. “This is a pivotal time for our industry, and we look forward to collaborating with our Board of Directors to continue advocating for our members and advancing our mission to foster innovation for the future of life sciences and ultimately improve patients’ lives.”
The new board members were elected by the NewYorkBIO membership in recognition of their leadership in the life science community. Through their roles, the Board aims to
guide NewYorkBIO on their mission to advance the industry statewide and influence policy at a time of increased investment in healthcare research and innovation. The board will also oversee NewYorkBIO’s efforts to convene and support bioscience companies, universities, research institutions, and other organizations that are committed to improving health outcomes throughout New York and around the world.
To learn more about NewYorkBIO, please visit newyorkbio.org.
As the leading advocate for the life science community in New York, NewYorkBIO brings together hundreds of New York’s bioscience companies, universities, research institutions, and others dedicated to advancing life science research and commercializing treatments and cures for patients. NewYorkBIO connects key voices and companies of all sizes with resources to initiate and support transformative change to impact patient outcomes.